Thomas Liu

发表

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.

M. Schiff, R. Fleischmann, J. Schechtman, 2004, Arthritis and rheumatism.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

A. Keech, R. Giugliano, M. Sabatine, 2017, The New England journal of medicine.

Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Joseph G Ibrahim, Ming-Hui Chen, H Amy Xia, 2012, Biometrics.

Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America

R. Muirhead, J. Maca, A. Dmitrienko, 2007 .

AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody in

R. Giugliano, M. Sabatine, N. Desai, 2014, Journal of the American College of Cardiology.

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab

R. Giugliano, M. Sabatine, N. Desai, 2017, JAMA cardiology.

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals

R. Giugliano, M. Sabatine, J. Gibbs, 2018, Journal of cardiovascular pharmacology and therapeutics.

Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program

Joseph G Ibrahim, Ming-Hui Chen, H Amy Xia, 2014, Statistics in medicine.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

R. Giugliano, M. Sabatine, N. Desai, 2012, The Lancet.

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

A. Keech, R. Giugliano, M. Sabatine, 2016, American heart journal.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

S. Wasserman, R. Scott, Thomas Liu, 2012, The Lancet.

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Abstract 16196: Impact of Baseline PCSK9 Levels on the Efficacy of Evolocumab, a Monoclonal Antibody Against PCSK9

R. Giugliano, M. Sabatine, N. Desai, 2014 .

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

R. Giugliano, M. Sabatine, F. Raal, 2014, Circulation.

Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic

Bohdana Ratitch, Wei Shen, Ming Zhou, 2020, Statistics in biopharmaceutical research.

Performance of some multiple testing procedures to compare three doses of a test drug and placebo

Huei Wang, Gary G. Koch, Lan Kong, 2005 .

Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.

D. Gudbjartsson, U. Thorsteinsdóttir, K. Stefánsson, 2023, JAMA.

Long term safety of etanercept in elderly subjects with rheumatic diseases

P. Peloso, M. Weisman, R. Fleischmann, 2005, Annals of the rheumatic diseases.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.